Related Experiment Videos
Quality of life in hypertension
I Os1
1Department of Internal Medicine, Ullevål Hospital, University of Oslo, Medical School, Norway.
Insights
Hypertension treatment impacts quality of life and compliance. This review summarizes comparative studies on antihypertensive agents, focusing on Angiotensin-Converting Enzyme (ACE) inhibitors and their effects.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Mild to moderate hypertension often presents asymptomatically.
- Treatment compliance can be negatively affected by quality of life impacts and side-effects of antihypertensive medications.
Purpose of the Study:
- To summarize comparative studies on quality of life with various antihypertensive agents.
- To specifically highlight the role and effects of Angiotensin-Converting Enzyme (ACE) inhibitors.
Main Methods:
- Review of existing comparative studies.
- Analysis of quality of life data related to antihypertensive treatments.
- Focus on studies involving ACE inhibitors.
Main Results:
- Comparative studies show varying impacts of antihypertensive agents on quality of life.
- ACE inhibitors are a key focus in the assessment of treatment tolerability and patient well-being.
- Quality of life considerations are crucial for improving patient compliance.
Conclusions:
- Antihypertensive treatment choice significantly influences patient quality of life and adherence.
- ACE inhibitors warrant specific consideration in managing hypertension due to their quality-of-life profile.
- Optimizing treatment based on quality of life can improve long-term hypertension management.
Abstract:
Mild to moderate hypertension is usually asymptomatic and therefore the impact on quality of life and side-effects of the antihypertensive treatment can have a negative effect on treatment compliance. A number of comparative studies have addressed quality of life issues with various antihypertensive agents, and the results of these studies are summarised in this article with particular reference to ACE inhibitors.